Triple-Negative Breast Cancer

Patients with triple-negative breast cancer experienced improved pathologic complete responses with the addition of neoadjuvant atezolizumab to chemotherapy.

“PD-L1 expression was significantly associated with pCR, which increased with higher PD-L1 expression on immune cells,” said Giampaolo Bianchini, an author of the NeoTRIPaPDL1 study.

Researchers suggested that these findings support using minimal residual disease as a major stratification variable in all clinical trials to be conducted in patients with triple negative breast cancer.

The phase 3 ASCENT trial designed to evaluate sacituzumab govitecan-hziy in patients with brain metastasis-negative, metastatic triple-negative breast cancer met its primary end point of progression-free survival.

The combination demonstrated a statistically significant and clinically meaningful improvement in pathological complete response for the treatment of individuals with early triple-negative breast cancer, regardless of PD-L1 expression.

For the first time, researchers have isolated a subtype of gamma-delta T-cells that offers protection in women with triple-negative breast cancer.

The TOPACIO trial tested the PARP inhibitor niraparib plus pembrolizumab in women with triple-negative breast cancer.

A small early-phase trial tested the addition of the oncolytic virus T-VEC to neoadjuvant chemotherapy in patients with triple-negative breast cancer.

Researchers looked at the role of biomarkers associated with systemic inflammation among patients with triple-negative breast cancer.

A study using multigene panel testing identified several pathogenic variants associated with an increased risk of triple-negative breast cancer.

Nab-paclitaxel/carboplatin should be considered a first-line option in the setting of triple-negative breast cancer.

Two new studies have found that some HER2-positive and triple-negative breast cancer patients can avoid sentinel lymph node biopsy after neoadjuvant systemic therapy.

Triple-negative breast cancer treatments being investigated include checkpoint inhibitors, agents that target the androgen receptor pathways, and antibody-drug conjugates.

An antibody–drug conjugate known as sacituzumab govitecan demonstrated significant clinical activity in heavily pretreated patients with relapsed/refractory metastatic triple-negative breast cancer, according to a new study.

In this Q&A we discuss the role of PARP inhibitors in cancer treatment, their role in triple-negative breast cancer patients and look forward to ongoing trials in this setting.

The AKT inhibitor ipatasertib offered improved progression-free survival over placebo when combined with paclitaxel in women with triple-negative breast cancer.

The use of neoadjuvant chemotherapy increases eligibility for breast-conserving therapy in triple-negative breast cancer patients, yet many still opt for mastectomy.

The use of a four-gene signature identified a series of subgroups of triple-negative breast cancer, including one subtype that was responsive to platinum-based chemotherapy in the metastatic setting.

In this interview we discuss long-term data on the anti–PD-L1 immunotherapy atezolizumab in metastatic triple-negative breast cancer.

Relatively few clinically important therapeutic advances have occurred in the treatment of triple-negative breast cancer since the introduction of taxanes as adjuvant therapy over 20 years ago. However, this is rapidly changing due to a variety of conceptually important clinical trials and emerging new options.

A triplet regimen including paclitaxel, capecitabine, and bevacizumab showed efficacy and safety in women with advanced triple-negative breast cancer.

A 40-year-old woman noted a large mass in her right breast. A diagnostic mammogram and ultrasound confirmed a 3.4-cm mass with associated microcalcifications.

The KEYNOTE-012 trial shows that pembrolizumab has activity and acceptable toxicity as single-agent therapy in advanced triple-negative breast cancer.

Two leading breast cancer experts debated the proposition that platinum-based or other additional systemic agents should be used in difficult-to-treat cases of high-risk triple-negative breast cancer.

In this interview we discuss the current challenges to treating triple-negative breast cancer and look at avenues of promising research.